Overview

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

Status:
Completed

Trial end date:
2020-12-16

Target enrollment:

Participant gender:

Summary

The purpose of this study to evaluate the safety, tolerability and pharmacokinetics (PK) of lanadelumab administered by Intravenous (IV) infusion in healthy adult volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Collaborator:

Takeda Development Center Americas, Inc.